Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736185 | 0.85 | CDC7 (0.46) | CDC7DBF4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10365452 | 0.83 | CYP3A4 (0.38) | CDC7DBF4CCNE1CDK2CYP1A2 | |
| SCHEMBL10365732 | 0.83 | CDC7 (0.51) | CDC7DBF4CCNCCDK8CYP1A2 | |
| Hydrochloric Acid SCHEMBL10365286 | 0.83 | CDC7 (0.40) | CDC7DBF4CCNE1CDK2CYP1A2 | |
| SCHEMBL2958703 | 0.81 | PIK3CD (0.59) | MAPTMEN1NPC1CASP3RAB9A | |
| SCHEMBL10365699 | 0.81 | CDC7 (0.45) | CDC7DBF4CCNE1CDK2MAPK14 | |
| SCHEMBL10365735 | 0.81 | CDC7 (0.39) | CDC7DBF4CCNE1CDK2CYP1A2 | |
| SCHEMBL3156596 | 0.80 | CCNC (0.46) | CCNCCDK8TBK1MAPK14PIK3CD | |
| SCHEMBL10366994 | 0.79 | SIRT3 (0.47) | CDC7DBF4CCNE1CDK2CCNC | |
| SCHEMBL3164908 | 0.79 | IKBKB (0.38) | MEN1NPC1CASP3RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060148693-A1 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | claimed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-0199968-B1 | THIAZOLE DERIVATIVES | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-02-28 | — | — | EP | claimed |
| US-4804668-A | CARDIOTONIC AGENTS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-02-14 | — | — | US | claimed |
| EP-0199968-A1 | Thiazole derivatives | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-11-05 | — | — | EP | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| US-4804668-A | CARDIOTONIC AGENTS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-02-14 | — | — | US | disclosed |
| EP-0199968-A1 | Thiazole derivatives | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | CDC7 2834/4885DBF4 540/4885CCNE1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.